Recombinant DNA encoding novel family of primate hematopoietic growth factors
Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
Method of inducing leukocytosis with a combination of IL-3 and GM-CSF
Cysteine added variants of interleukin-3 and chemical modifications thereof
Human Interleukin-3(Il-3) variants and their use to promote or antagonize IL-3-mediated processes
Interleukin-3 (IL-3) mutant polypeptides and their recombinant production Patent #: 5677149
ApplicationNo. 471039 filed on 06/06/1995
US Classes:424/85.2, Interleukin930/141Interleukin
ExaminersPrimary: Fitzgerald, David L.
Attorney, Agent or Firm
Foreign Patent References
International ClassesA61K 038/20
AbstractThe present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins). These hIL-3 muteins contain one to three amino acid substitutions and may also have amino acid deletions at both the N- and C- termini. The invention also relates to pharmaceutical compositions containing the hIL-3 muteins and methods for using them. Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the hIL-3 muteins, related microbial expression systems, and processes for making the hIL-3 muteins using the microbial expression systems. Included in the present invention are deletion mutants of hIL-3 in which from 1 to 14 amino acids have been deleted from the N-terminus, and from 1 to 15 amino acids (corresponding to residues 119 to 133) have been deleted from the C-terminus, and which also contain one to three amino acid substitutions in the polypeptide. These hIL-3 mutant polypeptides may have biological activities similar to or better than hIL-3 and, in some cases, may also have an improved side effect profile.